Cirrhosis Discriminate Score (CDS) calculation.

<p>Cirrhosis Discriminate Score (CDS) calculation.</p

Non-invasive tests (NITs) values before and after treatment.

<p>Non-invasive tests (NITs) values before and after treatment.</p

Multivariable logistic regression for Grading, ETR and Relapse.

<p>OR: odds ratio—CI: 95% confidence interval</p><p>^a: odds ratio and confidence intervals have been calculated considering an interval of 10 years.</p><p>^b: odds ratio and confidence intervals have been calculated considering an interval of 10⁵ units of viremia</p><p>^c: odds ratio and confidence intervals have been calculated considering an interval of 20 units of GGT</p><p>Multivariable logistic regression for Grading, ETR and Relapse.</p

Non-invasive tests (NITs) values distribution at baseline and after an SVR.

<p>Non-invasive tests (NITs) values distribution at baseline and after an SVR.</p

Viral genome architecture of the defective forms identified in the serum of chronic hepatitis C patients (genotype 1 HCV).

<p>(A) Pictures of agarose-gel showing amplicons obtained after the second round of nested PCR for all the patients in which defective forms were identified (lanes 1–25) and a subset of patients negative for the defective form (lanes 26–36). Lanes M: molecular size markers. (B) Schematic representation of the architecture of the 25 defective variants identified in the sera of subjects chronically infected with genotype 1 HCV. (C) Picture of agarose gel showing amplicons obtained after nested PCR performed on synthetic HCV RNA mixtures assessing full-length/defective ratios from 1 to 1000 (lanes 3–12). FL: full-length RNA only (lane 1); D: deleted RNA only (lane 2). Lane M: molecular size markers.</p

Demographic and clinical features of the 132 HCV1 patients, stratified by presence of HCV defective particles or IL28B genotype.

<p>Continuous variables are expressed as median ± interquartile range (IQR). P values are calculated by Wilcoxon test and Fisher's test for continuous and categorised variables respectively; NS: not significant.</p><p>Demographic and clinical features of the 132 HCV1 patients, stratified by presence of HCV defective particles or IL28B genotype.</p

Quantitative detection of total and defective HCV RNA in a subset of patients who carried defective HCV forms.

<p>Quantitative detection of total and defective HCV RNA in a subset of patients who carried defective HCV forms.</p

Virogical responses to PEG-IFNα/RBV stratified for HCV defective forms or IL28B genotype.

<p>RVR, EVR, ETR and SVR rates in the overall population as well as relapse rates in ETR-positive subjects, according to the presence of HCV deletions (A-B) or IL28B genotype (C-D), are reported. The presence of HCV defective particles does not have a significant effect on RVR, EVR, ETR or SVR rates, while it correlates with a higher probability of relapse in ETR-positive subjects (A-B). IL28B CT/TT genotypes are significantly associated with lower RVR, EVR, ETR and SVR rates and correlate with a higher probability of relapse (C-D).</p

Median^# NIT values at post-SVR liver biopsy and reference cut-offs for the diagnosis of cirrhosis.

<p>Median<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0155967#t003fn001" target="_blank">^#</a> NIT values at post-SVR liver biopsy and reference cut-offs for the diagnosis of cirrhosis.</p

Patients' characteristics at the time of post-SVR liver biopsy.

<p>Patients' characteristics at the time of post-SVR liver biopsy.</p